Home Latest Articles
Latest Articles
  • Nianli ZENG, Xiaolan WANG, Yanyan GUO, Xiaocong PU
    Chinese Journal of Pharmaceuticals. 2025, 56(9): 1215-1219.

    In order to meet the regulatory requirements for halide identification of pharmaceutical rubber stoppers(mainly chlorinated and brominated rubber stoppers) in packaging material changes and generic drug research and development, a rapid and accurate method based on pretreatment of ignition residue and ion chromatography detection was established. After ignition and ashing, residual ions in samples were extracted with water. The Dionex IonPac™ AS19 column was used, with 20 mmol/L potassium hydroxide solution as eluent, at a flow rate of 1 mL/min, column temperature of 30 ℃, and injection volume of 25 μL. The results showed that it was linear for chloride and bromine ions in the range of 2 - 100 μg/mL, with satisfactory recovery and strong method specificity. The method was applied to determine 16 batches of halogenated butyl rubber stoppers from different manufacturers, and the determination results were completely consistent with the formulations claimed by the manufacturers. This simple, rapid, and accurate method enables effective identification and quantitative detection of halides in pharmaceutical stoppers, providing reliable technical support for packaging material changes of marketed drugs, generic drug packaging screening, and quality control of rubber stoppers.

  • Qilei ZHU, Tianyi CHEN-ZHUANG, Meng CAO
    Chinese Journal of Pharmaceuticals. 2025, 56(9): 1220-1224.
  • Ruibo JIA, Guilian XU, Dan LU, Shanshan GONG, Xiangang LI
    Chinese Journal of Pharmaceuticals. 2025, 56(9): 1225-1229.
  • Beiyan SHU, Qinghua WANG, Lei LIU, Jia GENG, Lifang SUN, Jie ZHOU, Wenjun GENG
    Chinese Journal of Pharmaceuticals. 2025, 56(9): 1230-1236.
  • Tiantian XIA, Hui WANG, Zeyu ZHOU
    Chinese Journal of Pharmaceuticals. 2025, 56(9): 1237-1242.
  • Qinghui FU, Jie LIU, Jun HE
    Chinese Journal of Pharmaceuticals. 2025, 56(8): 975-983.

    Metabolic associated fatty liver disease(MAFLD) is a liver disease characterized by hepatic steatosis,accompanied by metabolic abnormality. In recent years, the incidence of MAFLD has significantly increased due to lifestyle changes and rising obesity rates, becoming an important public health challenge globally. Despite advancements in mechanistic understanding and escalating research efforts on therapeutic agents, effective pharmacological interventions for MAFLD remain limited. Notably, the development of potential therapeutics is often hindered by critical drawbacks such as poor stability, low bioavailability, and inadequate hepatic targeting. Nanoparticle drug delivery systems offer a promising solution by enhancing drug stability, improving solubility and bioavailability, and enabling precise hepatic targeting. This review primarily introduces the pathogenesis, diagnostic criteria, current treatment status, and challenges in drug development for MAFLD, with a particular focus on the application of nanoparticle drug delivery systems to MAFLD treatment, aiming to provide references for the development of therapeutic drugs for MAFLD.

  • Wenyu CUI, Di LIU, Qiao ZHANG, Chunyan LYU
    Chinese Journal of Pharmaceuticals. 2025, 56(8): 984-991.

    As an emerging transdermal drug delivery technology, microneedles can bypass the hepatic first-pass effect, effectively reducing the pain associated with traditional subcutaneous injections and realizing minimally invasive and painless drug administration. Polymer microneedles, characterized by their excellent mechanical properties and biocompatibility, can accurately penetrate the stratum corneum to create microchannels, significantly enhancing the efficiency of transdermal drug delivery. They have found widespread application to diabetes management, dermatological treatments, and vaccine delivery. This review emphasizes the analysis of matrix materials utilized in the preparation of various types of polymer microneedles, and discusses the application of polymer microneedles with different matrix materials to vaccine delivery, dermatological treatment and diabetes management, while also addressing the specific applications of these materials and highlighting the challenges and future development trends in this field.

  • Zhiwei LIAO, Yonghai BU, Kangyong HE, Linjie ZHANG, Feng NI
    Chinese Journal of Pharmaceuticals. 2025, 56(8): 992-997.

    This study developed a new synthetic process of roxadustat(1). Starting from 5-phenoxyisobenzofuran-1(3H)-one(2), the process involved ring-opening with thionyl chloride followed by isoquinoline ring construction using sodium ethoxide to yield ethyl 4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(4). Compound 4 was then brominated with N-bromosuccinimide to afford ethyl 1-bromo-4-hydroxy-7-phenoxyisoquinoline-3-carboxylate(5). Next, compound 5 underwent Suzuki coupling with methylboronic acid under the catalysis of palladium acetate and triphenylphosphine to produce ethyl 4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxylate(6). Finally, compound 6 was condensed with glycine under activation by 1,8-diazabicyclo[5.4.0]undec-7-ene(DBU) followed by purification to afford the final product 1. The total yield was about 47.4%(based on 2) with the purity of 99.8%. This route features mild reaction conditions and controllable product quality, making it suitable for industrial production.

  • Wanchun GONG, Jianshu XIE, Guangxin XIA
    Chinese Journal of Pharmaceuticals. 2025, 56(8): 998-1002.

    The synthesis process of dabigatran etexilate mesylate(1) was improved. Using N-(4-cyanophenyl)-glycine(2) and 3-[(3-amino-4-methylaminobenzoyl)(pyridin-2-yl)amino]ethyl propionate(3) as the starting materials,1 was synthesized through amidation, cyclization, aminolysis, reduction, amidation and salinization. The overall yield was approximately 34.5%(based on 3), with a purity of 99.73%. The key step of the improvement lay in the preparation of ethyl 3-[[[2-[[(4-amidinophenyl)amino]methyl]-1-methyl-1H-benzimidazol-5-yl]carbonyl](pyridin-2-yl)amino]-propionate benzenesulfonate. This step abandoned the purification by column chromatography and the use of flammable solvent system, and also avoided the use of expensive Pd/C and heavily polluting Fe powder in the catalytic hydrogenation.The improved process features low cost, simple and safe operation, making it suitable for industrial production.

  • Qiming GUAN, Fengxiang ZHANG, Bingyang ZENG, Yawei LI, Ying PENG
    Chinese Journal of Pharmaceuticals. 2025, 56(8): 1003-1010.

    Based on the industrial synthetic route of orlistat(1), eight related substances of 1 were synthesized,namely L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester(related substance A), (2S,3S,5S)-5-[(N-formyl-L-leucyl)oxy]-2-hexyl-3-hydroxyhexadecanoic acid(related substance B), N-formyl-L-leucine [S-(E)]-1-(2-nonenyl)dodecyl ester(related substance C), N-formyl-L-leucine (3S,4S,6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-yl ester(related substance D), N-formyl-L-leucine (3S,4R,6S)-3-hexyl-2-oxo-6-undecyltetrahydro-2H-pyran-4-yl ester(related substance E), N-formyl-L-isoleucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester(related substance F), N-formyl-L-leucine 1-[(2S,3S)-2-hydroxy-3-[1-phenyl-(R)-ethylcarbonylamino]nonyl]dodecyl ester(related substance G), N-formyl-D-leucine (S)-l-[[(2S,3S)-3-hexyl-4-oxo-2-oxacyclobutyl]methyl]dodecyl ester(related substance H). Their structures were confirmed by 1H NMR, 13C NMR and MS. The synthetic methods of related substance A, B, F and G were reported for the first time.

News